Fulcrum Therapeutics, Inc.
FULC Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.64
KIRA · Stoqly’s AI analyst, in plain words
- Fulcrum Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Fulcrum Therapeutics, Inc. lost $74.9M in fiscal 2025.
- Free cash flow was −$60.4M in fiscal 2025, — of revenue.
Market cap
$278M
P/E
—
Revenue
$0.0M
Net income
−$74.9M
Free cash flow
−$60.4M
Operating margin
—
Fulcrum Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$74.9M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Fulcrum Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Fulcrum Therapeutics, Inc.
- CIK
- 0001680581
Fulcrum Therapeutics, Inc. · FULC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $19.2M | $6.3M | $2.8M | $80.0M | $0.0M |
| Revenue growth | 117.2% | −66.9% | −55.8% | 2,752.0% | −100.0% |
| Operating margin | −423.0% | −1,774.9% | −3,945.2% | −27.4% | — |
| Net income | −$80.8M | −$110M | −$97.3M | −$9.7M | −$74.9M |
| Net margin | −421.9% | −1,732.4% | −3,470.1% | −12.2% | — |
| Diluted EPS | −$2.29 | −$2.44 | −$1.59 | −$0.16 | −$1.18 |
| Cash | |||||
| Cash from operations | −$78.5M | −$97.1M | −$91.0M | −$2.2M | −$60.1M |
| Capital expenditure | $1.7M | $2.0M | $0.5M | $0.3M | $0.3M |
| Free cash flow | −$80.2M | −$99.0M | −$91.5M | −$2.5M | −$60.4M |
| FCF margin | −418.5% | −1,561.2% | −3,261.1% | −3.1% | — |
| Share count change | 39.4% | 27.1% | 36.2% | 1.1% | 2.3% |
| Debt and strength | |||||
| Cash and short-term investments | $35.4M | $35.1M | $25.6M | $58.2M | $198M |
| Shareholders' equity | $212M | $199M | $235M | $243M | $349M |
| Current ratio | 11.8x | 12.4x | 17.7x | 22.6x | 27.4x |
| Returns and quality | |||||
| Return on equity | −52.7% | −53.5% | −44.8% | −4.1% | −25.3% |
| Return on tangible equity | −38.2% | −55.2% | −41.4% | −4.0% | −21.5% |
| Piotroski F-score | 4 | 2 | 3 | 4 | 2 |
| Altman Z'' | 8.7 | 3.8 | 7.5 | 13.4 | 20.5 |
Insiders bought, 12 months
$1.5M
2 insiders
Insiders sold, 12 months
$59.0M
4 insiders
Of sales under plans
1%
$0.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Fulcrum Therapeutics, Inc. · FULC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.64 a share, the company is worth $278M.
Source: SEC EDGAR XBRL filings (CIK 0001680581). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.